TRIM21/Ro52 is responsible for the degradation of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway, and its feedback regulation on phosphatidylinositol 3-kinase (PI3K)/AKT pathway makes TRIM21/Ro52 a potential therapeutic target in PI3K/AKT activation cancer [113]. The gene discussed is G6PD; the disease is cancer.